68Ga- and 18F-CAIX PET Imaging Study (CAIX-PET)
A Prospective Randomized Study of 68Ga- and 18F-Labeled CAIX-Targeted PET/CT Imaging in Patients With Renal Tumors
This exploratory clinical imaging study will evaluate the safety, tolerability, biodistribution, lesion detection, and tumor uptake characteristics of 68Ga- and 18F-labeled carbonic anhydrase IX (CAIX)-targeted positron emission tomography/computed tomography (PET/CT) in patients with renal tumors or suspected renal cell carcinoma. Participants will be randomly assigned to receive either 68Ga-CAIX or 18F-CAIX PET/CT. All participants will also undergo 18F-FDG PET/CT for comparison. The study will further explore the association between CAIX-targeted PET findings and CAIX expression assessed by immunohistochemistry, as well as the diagnostic performance of CAIX-targeted PET/CT for lesion detection.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Tingting Yuan, M.D.
- Phone Number: 13051707479
- Email: biluohtt@163.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 010000
- Recruiting
- Department of Nuclear Medicine, Peking University First Hospital
-
Contact:
- Tingting Yuan, M.D.
- Phone Number: 010-83575252
- Email: biluohtt@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Adults aged 18 years or older. 2. Voluntarily provide written informed consent before participation. 3. Patients with an indeterminate renal mass, suspected renal cell carcinoma, previously diagnosed clear cell renal cell carcinoma, or suspected recurrent renal cell carcinoma based on clinical or imaging findings.
4. Estimated life expectancy of at least 6 months. 5. Participants of childbearing potential must use appropriate and highly effective contraception for at least 35 days after administration of the study tracer.
Exclusion Criteria:
-
1. Renal tumor known to represent metastasis from another primary malignancy. 2. Other active malignancies requiring treatment. 3. Chemotherapy, radiotherapy, or immunotherapy within 4 weeks before study enrollment.
4. Renal dysfunction with an estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m².
5. Uncontrolled psychiatric disorders that may interfere with study participation.
6. Pregnancy or breastfeeding. 7. Severe nonmalignant diseases, including infectious, autoimmune, or metabolic diseases, that in the investigator's opinion may interfere with the study objectives, participant safety, or study compliance.
8. Individuals belonging to vulnerable populations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 68Ga-CAIX PET/CT
Participants randomized to this arm will receive a single intravenous administration of 68Ga-CAIX followed by PET/CT imaging approximately 1 hour after tracer administration. Participants will also undergo 18F-FDG PET/CT approximately 48 hours before or after the 68Ga-CAIX PET/CT examination according to the randomized imaging sequence. |
68Ga-labeled CAIX-targeted PET tracer administered as a single intravenous injection at approximately 0.08-0.10 mCi/kg, followed by PET/CT imaging approximately 1 hour after administration. |
|
Experimental: 18F-CAIX PET/CT
Participants randomized to this arm will receive a single intravenous administration of 18F-CAIX followed by PET/CT imaging approximately 1 hour after tracer administration. Participants will also undergo 18F-FDG PET/CT approximately 48 hours before or after the 18F-CAIX PET/CT examination according to the randomized imaging sequence. |
18F-labeled CAIX-targeted PET tracer administered as a single intravenous injection at approximately 0.08-0.10 mCi/kg, followed by PET/CT imaging approximately 1 hour after administration. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Semiquantitative Uptake of CAIX-Targeted Tracers
Time Frame: During the PET/CT examination, approximately 60 minutes after 18F-CAIX or 68Ga-CAIX administration.
|
CAIX-targeted tracer uptake will be quantified using the maximum standardized uptake value (SUVmax) measured by PET/CT in predefined normal organs and tumor lesions. |
During the PET/CT examination, approximately 60 minutes after 18F-CAIX or 68Ga-CAIX administration.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Adverse Events
Time Frame: From tracer administration through 24 hours after PET/CT imaging.
|
The incidence of adverse events occurring after administration of 68Ga-CAIX or 18F-CAIX will be recorded to assess the safety and tolerability of the CAIX-targeted tracers. |
From tracer administration through 24 hours after PET/CT imaging.
|
|
Correlation Between CAIX PET Uptake and CAIX Immunohistochemical Expression
Time Frame: Within 4 weeks after PET/CT examination, at the time of pathological evaluation.
|
The correlation between CAIX PET uptake, measured by SUVmax on CAIX-targeted PET/CT, and CAIX immunohistochemical expression, quantified using the H-score, will be assessed using the Spearman correlation coefficient. |
Within 4 weeks after PET/CT examination, at the time of pathological evaluation.
|
|
Number of Lesions Detected by CAIX-Targeted PET/CT
Time Frame: During the PET/CT examination, approximately 60 minutes after 18F-CAIX or 68Ga-CAIX administration.
|
The number of tumor lesions detected by 68Ga-CAIX or 18F-CAIX PET/CT will be recorded and compared with the number of lesions identified by 18F-FDG PET/CT and available clinical, pathological, and imaging reference standards. |
During the PET/CT examination, approximately 60 minutes after 18F-CAIX or 68Ga-CAIX administration.
|
|
Sensitivity of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
The sensitivity of 68Ga-CAIX or 18F-CAIX PET/CT for detecting tumor lesions will be calculated as the percentage of reference-standard-positive lesions correctly identified by CAIX-targeted PET/CT. |
From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
|
Specificity of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
The specificity of 68Ga-CAIX or 18F-CAIX PET/CT for detecting tumor lesions will be calculated as the percentage of reference-standard-negative lesions correctly identified as negative by CAIX-targeted PET/CT. |
From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
|
Accuracy of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
The accuracy of 68Ga-CAIX or 18F-CAIX PET/CT for lesion detection will be calculated as the percentage of lesions correctly classified as positive or negative according to the clinical, pathological, and imaging reference standards. |
From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
|
False-Positive Rate of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
The false-positive rate of 68Ga-CAIX or 18F-CAIX PET/CT for lesion detection will be calculated as the percentage of reference-standard-negative lesions incorrectly identified as positive by CAIX-targeted PET/CT. |
From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
|
False-Negative Rate of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
The false-negative rate of 68Ga-CAIX or 18F-CAIX PET/CT for lesion detection will be calculated as the percentage of reference-standard-positive lesions incorrectly identified as negative by CAIX-targeted PET/CT. |
From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Urologic Neoplasms
- Carcinoma
- Kidney Neoplasms
- Carcinoma, Renal Cell
Other Study ID Numbers
Other Study ID Numbers
- CAIX 001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data underlying the results reported in the study, after de-identification.
IPD Sharing Time Frame
Beginning 12 months after publication of the study results and ending 36 months after publication.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.